• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human psychopharmacology: clinical and experimental >Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: A randomized open label trial.
【24h】

Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: A randomized open label trial.

机译：米氮平的疗效和耐受性舍曲林与创伤后韩国退伍军人应激障碍:一个随机开放标签试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The aim of this study was to investigate the potential use of mirtazapine in Korean veterans diagnosed with PTSD, by comparing it with sertraline, a drug approved for use in PTSD in the USA. METHODS: Efficacy was evaluated by the clinician administered PTSD scale (CAPS-2), the Hamilton rating scale for depression (HAMD-17) and the clinical global impression scale (CGI), at baseline and at weeks 1, 2 and 6. A response was defined as a >/= 30 % decrease in CAPS-2 total severity, a >/= 50 % decrease in total HAMD-17 score, and a CGI-I score < 3. RESULTS: 51 patients on mirtazapine (mean age/duration of illness: 59.1/33.5 years) and 49 on sertraline (mean age/duration of illness: 60.6/35.6 years) completed the study. The mean daily dosage was 34.1 mg for mirtazapine and 101.5 mg for sertraline. On the CAPS-2 total score more patients responded in the mirtazapine group at week 1 (13 vs 2 %) and week 2 (51 vs 31 %). At week 6 this difference was statistically significant (88 % vs 69 %, p = 0.039)on the CAPS-2 total score. The HAMD-17 total score and CGI-I score decreased in both groups, with no significant differences between th groups on all time points. The main side effects for the mirtazapine group were: dry mouth (19.6 %), constipation (19.6 %), somnolence (15.7 %) and weight gain (1.96 %); and for the sertraline group: indigestion (14.3 %), palpitation (6.1 %), agitation (2.0 %), epigastric soreness (2.0 %), insomnia (2.0 %) and sexual dysfunction (2.0 %). CONCLUSION: Mirtazapine appeared to be an effective and well-tolerated treatment for PTSD in Korean veterans. Copyright 2004 John Wiley & Sons, Ltd.
机译：背景:本研究的目的是调查米氮平的潜在用途韩国人被确诊患有PTSD的退伍军人,通过比较舍曲林,药物被批准用于在美国创伤后应激障碍。由临床医生管理PTSD的规模(CAPS-2),汉密尔顿量表抑郁症(HAMD-17)和临床全球印象量表(CGI)、基线和周1、2和6。减少CAPS-2总严重性,> / = 50%减少总HAMD-17得分,CGI-I分数< 3。(平均年龄/疾病持续时间:59.1/33.5年)和49舍曲林(平均年龄/持续时间疾病:60.6/35.6年)完成了研究。米氮平平均每日剂量为34.1毫克舍曲林和101.5毫克。米氮平进更多的病人组1 (13 vs 2%)和2周(51 vs 31%)。显著(88%比69%,p = 0.039)CAPS-2总分。CGI-I两组得分降低,没有之间的显著差异组所有时间点。米氮平组:口干(19.6%)、便秘(19.6%)、嗜眠症(15.7%)和体重增加(1.96%);组:消化不良(14.3%)、心悸(6.1%),搅拌(2.0%)、上腹部疼痛(2.0%),失眠(2.0%)和性功能障碍(2.0%)。结论:米氮平似乎是一个有效,同时治疗创伤后应激障碍在韩国退伍军人。儿子,有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号